Fly News Breaks for March 18, 2019
Mar 18, 2019 | 06:42 EDT
BTIG analyst Thomas Shrader initiated Momenta (MNTA) with a Neutral rating, saying that while he is positive on the company's IVIg-focused re-positioning, the stock is not cheap and the proof-of-concept for its analytical focus is at least a year away. The analyst also states that the bulk of his modeled value for the company comes from its pipeline development in treating maternal-fetal autoimmune disease, noting that competition in the space is "fierce" and that Momenta is "significantly behind Argenx (ARGX) in the development of FcRn blockers.
News For MNTA;ARGX From the Last 2 Days
There are no results for your query MNTA;ARGX